Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $45.8 million.

  • Aytu Biopharma's Non-Current Assets fell 1394.48% to $45.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $45.8 million, marking a year-over-year decrease of 1394.48%. This contributed to the annual value of $45.0 million for FY2025, which is 1993.81% down from last year.
  • Latest data reveals that Aytu Biopharma reported Non-Current Assets of $45.8 million as of Q4 2025, which was down 1394.48% from $43.9 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Non-Current Assets ranged from a high of $171.5 million in Q1 2021 and a low of $43.9 million during Q3 2025
  • Moreover, its 5-year median value for Non-Current Assets was $63.8 million (2023), whereas its average is $79.3 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 10602.53% in 2021, then crashed by 5157.26% in 2022.
  • Aytu Biopharma's Non-Current Assets (Quarter) stood at $136.3 million in 2021, then crashed by 48.03% to $70.8 million in 2022, then fell by 15.46% to $59.9 million in 2023, then fell by 11.2% to $53.2 million in 2024, then dropped by 13.94% to $45.8 million in 2025.
  • Its Non-Current Assets was $45.8 million in Q4 2025, compared to $43.9 million in Q3 2025 and $45.0 million in Q2 2025.